专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160184253A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF RETINOIDS AND RETINOID-RELATED COMPOUNDS 审中-公开
标题翻译：雷诺霉素和与雷公藤相关的化合物的高渗透性原料组合物
公开(公告)号：US20160184253A1
公开(公告)日：2016-06-30
申请号：US14877788
申请日：2015-10-07
申请人： SUZHOU TECHFIELDS MEDICAL LTD.
发明人： Chongxi YU
IPC分类号： A61K31/21 , A61K31/216 , A61K31/4453 , G01N33/50
CPC分类号： A61K31/215 , A61K31/21 , A61K31/216 , A61K31/221 , A61K31/4453 , A61K47/54 , C07C219/10 , C07C2601/16 , C07C2602/10 , G01N33/502
摘要： The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
摘要翻译：本发明提供了能够穿过具有高穿透效率的生物屏障的类视黄醇和类视黄醇相关化合物的新型高渗透组合物（HPC）或高渗透前药（HPP）的组合物。 HPP在穿过生物屏障后能够转化为亲本活性药物或药物代谢物，因此可以对母体药物或代谢物可以进行的处理。此外，HPP能够达到母体药物可能无法进入或在目标区域提供足够浓度的区域，从而进行新的治疗。 HPP可以通过各种施用途径施用于受试者，例如局部递送至具有高浓度或系统地施用于生物受试者的病症的作用部位并以更快的速率进入总体循环。

2. 发明申请

US20160002157A1 NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES 有权
标题翻译：新型高渗透药物及其治疗帕金森病的组合物
公开(公告)号：US20160002157A1
公开(公告)日：2016-01-07
申请号：US14854616
申请日：2015-09-15
申请人： SUZHOU TECHFIELDS MEDICAL LTD.
发明人： Chongxi YU , Lina XU
IPC分类号： C07C317/44 , C07C271/22 , C07D211/62 , C07D471/04 , C07D321/12 , A61K31/40 , C07C219/32 , C07C219/06 , C07C327/36 , A61K31/24 , A61K31/197 , A61K31/277 , C07C237/08 , C07D207/16
CPC分类号： C07D471/04 , A61K31/137 , A61K31/195 , A61K31/197 , A61K31/198 , A61K31/24 , A61K31/277 , A61K31/40 , C07C217/60 , C07C219/06 , C07C219/10 , C07C219/14 , C07C219/28 , C07C219/32 , C07C229/12 , C07C229/36 , C07C229/58 , C07C237/06 , C07C237/08 , C07C237/20 , C07C271/16 , C07C271/22 , C07C317/44 , C07C327/30 , C07C327/36 , C07C2602/08 , C07D207/16 , C07D211/62 , C07D321/12 , C07D455/02 , C07K5/0806 , C07K5/0823 , A61K2300/00
摘要： One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
摘要翻译：本发明的一个方面提供了用于治疗帕金森病的新型高渗透组合物（HPC）或高渗透性前药（HPP）的组合物。 HPC / HPP能够在穿过生物屏障之后转化为亲本活性药物或药物代谢物，因此可以对母体药物或代谢物可以进行的处理。此外，HPP能够达到母体药物可能无法进入或在目标区域提供足够浓度的区域，从而进行新的治疗。 HPC / HPP可以通过各种施用途径施用于受试者，例如局部递送至具有高浓度或系统地施用于生物受试者的病症的作用部位并以更快的速率进入总体循环。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式